Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patients pretreated with various systemic thera...

Full description

Bibliographic Details
Main Authors: Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Gastroenterology
Subjects:
Hepatocellular carcinoma
Ramucirumab
Late-line
REACH-2
Online Access:https://doi.org/10.1186/s12876-023-02674-x

Internet

https://doi.org/10.1186/s12876-023-02674-x

Similar Items